Pralsetinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 287 publications

Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)

Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: May 20, 2026

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

Journal: Pharmacological research

Published: May 05, 2026

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 26, 2026

GDNF-RET signaling drives pulmonary neuroendocrine cell hyperplasia and allergic airway inflammation.

GDNF-RET signaling drives pulmonary neuroendocrine cell hyperplasia and allergic airway inflammation.

Journal: FEBS letters

Published: March 09, 2026

Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report.

Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report.

Journal: Lung Cancer (Auckland, N.Z.)

Published: February 28, 2026

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Journal: Tumori

Published: February 06, 2026

Cancer-linked ANKRD26-RET uses an unusual combination of pathomechanisms leading to strongly increased cell proliferation.

Cancer-linked ANKRD26-RET uses an unusual combination of pathomechanisms leading to strongly increased cell proliferation.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 04, 2026

RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases.

RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases.

Journal: Cell death & disease

Published: February 04, 2026

Unlocking catalytic capacity of (S)-selective ω-transaminases toward aryl methyl ketones via pocket engineering and droplet screening.

Unlocking catalytic capacity of (S)-selective ω-transaminases toward aryl methyl ketones via pocket engineering and droplet screening.

Journal: Bioresource technology

Published: February 02, 2026

Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.

Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.

Journal: Pathology, research and practice

Published: January 21, 2026

FGFR3-TACC3 fusion as a potential primary resistance mechanism to EGFR-TKI in lung adenocarcinoma harboring co-driven mutations: a case report.

FGFR3-TACC3 fusion as a potential primary resistance mechanism to EGFR-TKI in lung adenocarcinoma harboring co-driven mutations: a case report.

Journal: Frontiers in oncology

Published: January 16, 2026

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 23, 2025

Showing 1-12 of 287

Last Updated: 06/30/2026